Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC)

中部地区

• 批准号: 104232
• 金额: $ 1099.46万
• 依托单位: UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104232
• 关键词: Midlands; Wales; Advanced; Therapy; Treatment

"ATMPs, which can be _cell or gene therapies_, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers.ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are developed and shown to be effective, there are **major challenges in rolling them out to patients**. The reasons for this include: complexities in transporting a 'living' product, and lack of familiarity with such products in most NHS hospitals.The project lead is the Birmingham Biomedical Research Centre, a national centre of excellence. The Welsh government has also made a major investment in cell therapy and is supportive of NHS Wales as the joint-lead on this project. We are a **team of industrialists, clinicians, academics and computer system experts** who have all the necessary skills to succeed in this project.Our group **covers the Midlands and Wales** giving us access to major teaching hospitals and almost 15 million people providing a unique opportunity to set cell therapy up to succeed.We will:-Set up a network of hospitals with medical staff trained to receive and administer ATMPs.-Build seamless supply chains that ensure that 'living medicines' remain healthy and effective as they are moved from the production laboratory to the bedside.-Put in place the IT systems to manage the end-to-end process.-Validate this new infrastructure using real ATMPs-Deliver a programme that uses this infrastructure to speed up the testing of ATMPs in clinical trials.-Set-up protocols to test whether the **cost of a new ATMP is justified by its clinical effectiveness.**The benefits of MW-ATTC are (a) Patients with challenging illnesses will get access to breakthrough medicines; (b) ATMP companies will get access to the clinical mainstream and market; (c) Investment in this important industry sector will increase, as we demonstrate that the UK is an excellent location for ATMP R&D. MW-ATTC will be one of three Advanced Therapy Treatment Centres in the UK, working together for patients and ATMP innovators, to reinforce the UK's position as a world leader in this important field."

“ATMP 可以是细胞或基因疗法，在治疗目前治疗无法治愈的疾病方面显示出巨大的潜力。这些疾病包括关节炎、肝病、几种癌症和糖尿病溃疡。ATMP 才刚刚开始可用然而，即使新的 ATMP 疗法被开发出来并被证明是有效的，**将其推广到患者身上仍存在重大挑战**，原因包括：运输的复杂性。生活产品，以及大多数 NHS 医院对此类产品缺乏熟悉。该项目的牵头者是国家卓越中心伯明翰生物医学研究中心，威尔士政府也在细胞疗法方面进行了重大投资，并支持 NHS 威尔士作为联合牵头者。我们是一个由实业家、临床医生、学者和计算机系统专家组成的团队**，他们拥有在该项目中取得成功所需的所有技能。我们的团队**覆盖中部地区和威尔士**，使我们能够接触到主要的知识。教学医院和近 15数百万人为细胞疗法取得成功提供了独特的机会。我们将：-建立一个医院网络，配备接受和管理 ATMP 培训的医务人员。-建立无缝供应链，确保“活药物”保持健康和有效当它们从生产实验室转移到床边时。-部署 IT 系统来管理端到端流程。-使用真正的 ATMP 验证这个新基础设施-交付一个使用该基础设施来加速测试的程序ATMPs在临床中的应用试验。-建立协议来测试**新 ATMP 的成本是否与其临床有效性相匹配。**MW-ATTC 的好处是 (a) 患有挑战性疾病的患者将获得突破性药物； (b) ATMP公司将进入临床主流和市场； (c) 对这一重要行业领域的投资将会增加，因为我们证明英国是 ATMP 研发的绝佳地点。 MW-ATTC 将成为英国三个先进疗法治疗中心之一，共同为患者和 ATMP 创新者服务，以巩固英国在这一重要领域的世界领导者地位。”